Abstract
Imatinib mesylate--Gleevec (US), Glivec (worldwide), STI571--is an oral cancer drug that selectively inhibits several protein tyrosine kinases associated with human malignancy. The drug is used for the treatment of chronic myeloid leukemia, malignant gastrointestinal stromal tumors, and some other conditions. Treatment with imatinib is generally well tolerated but not without the risk of adverse effects. The risk of severe adverse events is low. Cutaneous side effects of this drug are common but muco-cutaneous lichenoid eruption with nail changes is very rare. We report a case of lichenoid eruption during imatinib therapy involving the skin, mucous membranes, and nails that cleared in spite of ongoing imatinib therapy.
MeSH terms
-
Administration, Oral
-
Administration, Topical
-
Adult
-
Benzamides
-
Clobetasol / administration & dosage
-
Drug Administration Schedule
-
Foot
-
Glucocorticoids / administration & dosage
-
Hand
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Lichenoid Eruptions / chemically induced*
-
Lichenoid Eruptions / drug therapy
-
Lichenoid Eruptions / pathology*
-
Male
-
Mouth Mucosa / pathology*
-
Nails / pathology*
-
Piperazines / adverse effects*
-
Prednisolone / administration & dosage
-
Protein Kinase Inhibitors / adverse effects*
-
Pyrimidines / adverse effects*
-
Skin / pathology*
-
Treatment Outcome
Substances
-
Benzamides
-
Glucocorticoids
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Imatinib Mesylate
-
Prednisolone
-
Clobetasol